Functional features defining the efficacy of cholesterol-conjugated, self-deliverable, chemically modified siRNAs

Nucleic Acids Research

Volumn 46, Issue 20, 2018, Pages 10905-10916

  Shmushkovich, Taisia ^a   Monopoli, Kathryn R ^a   Homsy, Diana ^a   Leyfer, Dmitriy ^a,b   Betancur Boissel, Monica ^a   Khvorova, Anastasia ^c   Wolfson, Alexey D ^a  

^a Advirna LLC   (United States)

^b BOSTON UNIVERSITY   (United States)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; SMALL INTERFERING RNA; ANTISENSE OLIGODEOXYNUCLEOTIDE; MAP4K4 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE;

3' UNTRANSLATED REGION; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; GENE ACTIVITY; GENE DELIVERY SYSTEM; GENE FUNCTION; GENE TARGETING; GENETIC ALGORITHM; GENETIC DATABASE; HUMAN; HUMAN CELL; LINEAR REGRESSION ANALYSIS; PREDICTION; PRIORITY JOURNAL; RNA SEQUENCE; THERMODYNAMICS; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; HELA CELL LINE; METABOLISM; NUCLEOTIDE SEQUENCE; RNA INTERFERENCE; RNA PROCESSING; SEQUENCE HOMOLOGY;

BASE SEQUENCE; CHOLESTEROL; GENE EXPRESSION REGULATION; HELA CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PROTEIN-SERINE-THREONINE KINASES; RNA INTERFERENCE; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA, SMALL INTERFERING; SEQUENCE HOMOLOGY, NUCLEIC ACID; THERMODYNAMICS;

EID: 85056588999     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gky745     Document Type: Article

References (45)

1. Schroeder, A., Levins, C.G., Cortez, C., Langer, R. and Anderson, D.G. (2010) Lipid-based nanotherapeutics for siRNA delivery. J. Intern. Med., 267, 9-21.
2. Kaczmarek, J.C., Kowalski, P.S. and Anderson, D.G. (2017) Advances in the delivery of RNA therapeutics: from concept to clinical reality. Genome Med., 9, 60.
3. Dowdy, S.F. (2017) Overcoming cellular barriers for RNA therapeutics. Nat. Biotechnol., 35, 222-229.
4. Khvorova, A. and Watts, J.K. (2017) The chemical evolution of oligonucleotide therapies of clinical utility. Nat. Biotechnol., 35, 238-248.
5. Huesken, D., Lange, J.A., Mickanin, C., Weiler, J., Asselbergs, F., Warner, J., Meloon, B., Engel, S., Rosenberg, A., Cohen, D. et al. (2005) Design of a genome-wide siRNA library using an artificial neural network. Nat. Biotechnol., 23, 995-1001.
6. He, F., Han, Y., Gong, J., Song, J., Wang, H. and Li, Y. (2017) Predicting siRNA efficacy based on multiple selective siRNA representations and their combination at score level. Sci. Rep., 7, 44836.
7. Pan, W.J., Chen, C.W. and Chu, Y.W. (2011) siPRED: predicting siRNA efficacy using various characteristic methods. PLoS One, 6, e27602.
8. Ahmed, F. and Raghava, G.P. (2011) Designing of highly effective complementary and mismatch siRNAs for silencing a gene. PLoS One, 6, e23443.
9. Qureshi, A., Thakur, N. and Kumar, M. (2013) VIRsiRNApred: a web server for predicting inhibition efficacy of siRNAs targeting human viruses. J. Transl. Med., 11, 305.
10. Ichihara, M., Murakumo, Y., Masuda, A., Matsuura, T., Asai, N., Jijiwa, M., Ishida, M., Shinmi, J., Yatsuya, H., Qiao, S. et al. (2007) Thermodynamic instability of siRNA duplex is a prerequisite for dependable prediction of siRNA activities. Nucleic Acids Res., 35, e123.
11. Shabalina, S.A., Spiridonov, A.N. and Ogurtsov, A.Y. (2006) Computational models with thermodynamic and composition features improve siRNA design. BMC Bioinformatics, 7, 65.
12. Vert, J.P., Foveau, N., Lajaunie, C. and Vandenbrouck, Y. (2006) An accurate and interpretable model for siRNA efficacy prediction. BMC Bioinformatics, 7, 520.
13. Czauderna, F., Fechtner, M., Dames, S., Aygun, H., Klippel, A., Pronk, G.J., Giese, K. and Kaufmann, J. (2003) Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res., 31, 2705-2716.
14. Lorenz, C., Hadwiger, P., John, M., Vornlocher, H.P. and Unverzagt, C. (2004) Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg. Med. Chem. Lett., 14, 4975-4977.
15. Layzer, J.M., McCaffrey, A.P., Tanner, A.K., Huang, Z., Kay, M.A. and Sullenger, B.A. (2004) In vivo activity of nuclease-resistant siRNAs. RNA, 10, 766-771.
16. Allerson, C.R., Sioufi, N., Jarres, R., Prakash, T.P., Naik, N., Berdeja, A., Wanders, L., Griffey, R.H., Swayze, E.E. and Bhat, B. (2005) Fully 2′-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J. Med. Chem., 48, 901-904.
17. Choung, S., Kim, Y.J., Kim, S., Park, H.O. and Choi, Y.C. (2006) Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem. Biophys. Res. Commun., 342, 919-927.
18. Koller, E., Propp, S., Murray, H., Lima, W., Bhat, B., Prakash, T.P., Allerson, C.R., Swayze, E.E., Marcusson, E.G. and Dean, N.M. (2006) Competition for RISC binding predicts in vitro potency of siRNA. Nucleic Acids Res., 34, 4467-4476.
19. Collingwood, M.A., Rose, S.D., Huang, L., Hillier, C., Amarzguioui, M., Wiiger, M.T., Soifer, H.S., Rossi, J.J. and Behlke, M.A. (2008) Chemical modification patterns compatible with high potency dicer-substrate small interfering RNAs. Oligonucleotides, 18, 187-200.
20. Jackson, A.L., Burchard, J., Leake, D., Reynolds, A., Schelter, J., Guo, J., Johnson, J.M., Lim, L., Karpilow, J., Nichols, K. et al. (2006) Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA, 12, 1197-1205.
21. Judge, A.D., Bola, G., Lee, A.C. and MacLachlan, I. (2006) Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol. Ther., 13, 494-505.
22. Hassler, M.R., Turanov, A.A., Alterman, J.F., Haraszti, R.A., Coles, A.H., Osborn, M.F., Echeverria, D., Nikan, M., Salomon, W.E., Roux, L. et al. (2018) Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo. Nucleic Acids Res., 46, 2185-2196.
23. Nair, J.K., Attarwala, H., Sehgal, A., Wang, Q., Aluri, K., Zhang, X., Gao, M., Liu, J., Indrakanti, R., Schofield, S. et al. (2017) Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates. Nucleic Acids Res., 45, 10969-10977.
24. Ligtenberg, M.A., Pico de Coana, Y., Shmushkovich, T., Yoshimoto, Y., Truxova, I., Yang, Y., Betancur-Boissel, M., Eliseev, A.V., Wolfson, A.D. and Kiessling, R. (2018) Self-delivering RNA interference targeting PD-1 improves tumor specific T cell functionality for adoptive cell therapy of malignant melanoma. Mol. Ther., 26, 1482-1493.
25. Chiu, Y.L. and Rana, T.M. (2003) siRNA function in RNAi: a chemical modification analysis. RNA, 9, 1034-1048.
26. Amarzguioui, M., Holen, T., Babaie, E. and Prydz, H. (2003) Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res., 31, 589-595.
27. Prakash, T.P., Allerson, C.R., Dande, P., Vickers, T.A., Sioufi, N., Jarres, R., Baker, B.F., Swayze, E.E., Griffey, R.H. and Bhat, B. (2005) Positional effect of chemical modifications on short interference RNA activity in mammalian cells. J. Med. Chem., 48, 4247-4253.
28. Dar, S.A., Gupta, A.K., Thakur, A. and Kumar, M. (2016) SMEpred workbench: a web server for predicting efficacy of chemicallymodified siRNAs. RNA Biol., 13, 1144-1151.
29. Dar, S.A., Thakur, A., Qureshi, A. and Kumar, M. (2016) siRNAmod: a database of experimentally validated chemically modified siRNAs. Sci. Rep., 6, 20031.
30. Matthews, J.C., Hori, K. and Cormier, M.J. (1977) Purification and properties of Renilla reniformis luciferase. Biochemistry, 16, 85-91.
31. O'Leary, N.A., Wright, M.W., Brister, J.R., Ciufo, S., Haddad, D., McVeigh, R., Rajput, B., Robbertse, B., Smith-White, B., Ako-Adjei, D. et al. (2016) Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation. Nucleic Acids Res., 44, D733-D745.
32. Khvorova, A., Reynolds, A. and Jayasena, S.D. (2003) Functional siRNAs and miRNAs exhibit strand bias. Cell, 115, 209-216.
33. Byrne, M., Tzekov, R., Wang, Y., Rodgers, A., Cardia, J., Ford, G., Holton, K., Pandarinathan, L., Lapierre, J., Stanney, W. et al. (2013) Novel hydrophobically modified asymmetric RNAi compounds (sd-rxRNA) demonstrate robust efficacy in the eye. J. Ocul. Pharmacol. Ther., 29, 855-864.
34. Alterman, J.F., Hall, L.M., Coles, A.H., Hassler, M.R., Didiot, M.C., Chase, K., Abraham, J., Sottosanti, E., Johnson, E., Sapp, E. et al. (2015) Hydrophobically Modified siRNAs Silence Huntingtin mRNA in Primary Neurons and Mouse Brain. Mol. Ther. Nucleic Acids, 4, e266.
35. Ly, S., Navaroli, D.M., Didiot, M.C., Cardia, J., Pandarinathan, L., Alterman, J.F., Fogarty, K., Standley, C., Lifshitz, L.M., Bellve, K.D. et al. (2017) Visualization of self-delivering hydrophobically modified siRNA cellular internalization. Nucleic Acids Res., 45, 15-25.
36. Kozomara, A. and Griffiths-Jones, S. (2014) miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res., 42, D68-D73.
37. Reynolds, A., Leake, D., Boese, Q., Scaringe, S., Marshall, W.S. and Khvorova, A. (2004) Rational siRNA design for RNA interference. Nat. Biotechnol., 22, 326-330.
38. Matranga, C., Tomari, Y., Shin, C., Bartel, D.P. and Zamore, P.D. (2005) Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell, 123, 607-620.
39. Elbashir, S.M., Martinez, J., Patkaniowska, A., Lendeckel, W. and Tuschl, T. (2001) Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J., 20, 6877-6888.
40. Zamore, P.D., Tuschl, T., Sharp, P.A. and Bartel, D.P. (2000) RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell, 101, 25-33.
41. Gredell, J.A., Berger, A.K. and Walton, S.P. (2008) Impact of target mRNA structure on siRNA silencing efficiency: a large-scale study. Biotechnol. Bioeng., 100, 744-755.
42. Liu, L., Li, Q.Z., Lin, H. and Zuo, Y.C. (2013) The effect of regions flanking target site on siRNA potency. Genomics, 102, 215-222.
43. Tafer, H., Ameres, S.L., Obernosterer, G., Gebeshuber, C.A., Schroeder, R., Martinez, J. and Hofacker, I.L. (2008) The impact of target site accessibility on the design of effective siRNAs. Nat. Biotechnol., 26, 578-583.
44. Foster, D.J., Brown, C.R., Shaikh, S., Trapp, C., Schlegel, M.K., Qian, K., Sehgal, A., Rajeev, K.G., Jadhav, V., Manoharan, M. et al. (2018) Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates. Mol. Ther., 26, 708-717.
45. Salomon, W.E., Jolly, S.M., Moore, M.J., Zamore, P.D. and Serebrov, V. (2015) Single-molecule imaging reveals that argonaute reshapes the binding properties of its nucleic acid guides. Cell, 162, 84-95.